$heff's $tation of $tocks & $olid DD

[ash111]

SPHS There is never 100% guarantee with bio(s) but based on risk/reward ratio and the very Solid Balance Sheet, i found this very interesting.Cash/Share= .78 PPS(13m/16.8m o/s), so worst case you lose 20%-40% of investment imo vs 500-1000% gain if successful P3, more if P2 cancer trial successful imo. Market Cap = only $15m (at .9 PPS)

Q2 numbers and comments:
ash111 Member Level Thursday, 09/17/15 03:43:03 PM
Re: None
Post # of 452

I saw the volume earlier..Cap is only $17m. for phase2 and phase 3!!!!....if good data out,this could see much higher pps.imo

vol.tripled on no posts here or at ymb.,so i believe the volume coming from solid sources.

(As of August 5, 2015, the registrant had 16,844,736 common shares (no par value) outstanding).

At June 30, 2015, we had cash, cash equivalents and securities available-for-sale of $13.2 million and net working capital of $11.6 million. We expect that our cash, cash equivalents and securities available-for-sale as of June 30, 2015 will be sufficient to fund our operations through the end of April 2016 assuming that we do not initiate any additional clinical development of PRX302. We will need to find additional capital to fund a second Phase 3 clinical trial of PRX302 for the treatment of the symptoms of BPH and for any future clinical development of PRX302 for the treatment of localized prostate cancer beyond our ongoing Phase 2a proof of concept clinical trial.

“In May we met our goal of dosing our first patients in a Phase 2a proof of concept trial of PRX302 in patients with localized low to intermediate risk prostate cancer,” stated Randall Woods, president and CEO of Sophiris Bio. “With the capital available, we are positioned to achieve clinical milestones from our ongoing trials in BPH and localized prostate cancer"...

http://investor.sophiris.com/index.cfm

June 2015 presentation:
Highlights pgs.33
"To
date
PRX302
appears
safe
and
well
tolerated"
http://files.shareholder.com/downloads/AMDA-1OKDCO/730922784x0x832479/218964C6-1987-4BF0-8256-5B06F22A532D/Sophiris_Bio_Inc_June_2015.pdf